Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Shares Outstanding (2023 - 2025)

Kura Oncology (KURA) has disclosed Shares Outstanding for 3 consecutive years, with $87.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 12.3% to $87.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $87.9 million, a 12.3% increase, with the full-year FY2025 number at $87.9 million, up 12.3% from a year prior.
  • Shares Outstanding was $87.9 million for Q4 2025 at Kura Oncology, up from $87.0 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $87.9 million in Q4 2025 to a low of $68.4 million in Q1 2023.
  • A 3-year average of $78.5 million and a median of $77.1 million in 2024 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: rose 3.07% in 2024, then rose 13.58% in 2025.
  • Kura Oncology's Shares Outstanding stood at $74.4 million in 2023, then grew by 5.22% to $78.2 million in 2024, then grew by 12.3% to $87.9 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Shares Outstanding are $87.9 million (Q4 2025), $87.0 million (Q3 2025), and $86.8 million (Q2 2025).